Japanese man gets 'dropped head syndrome' after using his phone too much
ALBAWABA - A 25-year-old Japanese man recently made headlines after being diagnosed with terrifying symptoms, described by doctors as the "dropped head syndrome," for using his phone excessively, leaving him with a bent neck.
First shared by JOS Case Reports, the photos revealed and warned people that using a phone while the user's head is bent down for prolonged periods of time can result in "dropped head syndrome." X-rays of the 25-year-old Japanese man who developed a bulge extruding from his neck revealed his deformed spine.
According to The Daily Mail, the man shared experiencing neck pains and difficulty swallowing food before being diagnosed with the condition. The doctors reported that the 25-year-old was an active child, but everything changed during his teenage years due to being targeted in a "serious bullying" incident by schoolmates.
(JOS Case Reports)
This prompted the man to drop out of school, shut himself inside his room, and play hours of video games with his neck bent, which eventually developed into dropped head syndrome.
After a series of scans and multiple failed attempts at getting his neck straight again using collars, the doctors were forced to surgically operate on the man after he developed a distorted vertebra and scar tissue. The patient could only lift his head six months after undergoing several surgical procedures in his neck.
Additionally, doctors issued a warning to individuals about excessive phone usage and targeted the youth as their main concern.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Bawaba
11-06-2025
- Al Bawaba
China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company's application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., also has been granted breakthrough therapy designation (BTD) by the NMPA. 'With the acceptance of our application for pimicotinib and the initiation of the priority review, we aim to offer patients in China the first approved systemic therapy for TGCT, addressing a tremendous unmet need in this country,' said Hong Chow, Head of China and International, Healthcare business of Merck. 'Pimicotinib has demonstrated the ability to not only shrink tumors that affect their joints but also improve outcomes like mobility, pain and stiffness, highlighting its potential to be a best-in-class treatment for TGCT. In parallel, we are working to file a New Drug Application to the US Food and Drug Administration, with additional filings planned in other markets.' TGCT is a locally aggressive and often recurring tumor of the joints that can cause high morbidity associated with swelling, pain, stiffness, and limited mobility of the affected joints, significantly impacting daily activities and quality of life in the primarily working-age population that it affects. If left untreated or in recurrent cases, TGCT can result in irreversible damage to the bone, joint and surrounding tissues. This highlights the need for well-tolerated and effective systemic treatments that can impact tumor growth while relieving the symptoms of the disease. The application is based on results from Part 1 of the global Phase 3 MANEUVER study, in which once-daily pimicotinib demonstrated a statistically significant improvement in the primary endpoint of objective response rate (ORR) assessed by blinded independent review committee (BIRC) compared with placebo at week 25 (54.0% vs. 3.2% for placebo; p<0.0001). The study also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT, including improvements in active range of motion and physical function and reductions in stiffness and pain. The data were presented earlier this month at the 2025 ASCO Annual Meeting.
Al Bawaba
10-06-2025
- Al Bawaba
CorroHealth Makes Strategic Investment in Gulf Capital's SANTECHTURE, Infusing CorroHealth AI Capabilities into SANTECHTURE RCM Products Throughout GCC Region
Gulf Capital, one of the largest private equity firms investing from the GCC to the rest of Asia, announced today that global healthcare technology company CorroHealth has made a strategic investment into one of its portfolio companies, Santechture, a Dubai based pioneering revenue cycle management (RCM) intelligent technology solutions deal brings together the industry-leading AI capabilities of CorroHealth with the advanced RCM solutions of SANTECHTURE, equipping SANTECHTURE healthcare clients across the Gulf Cooperation Council (GCC) region with powerful new technology to maximize investment formalizes what has been a productive working relationship between the two companies. Over the past two years, CorroHealth and SANTECHTURE have successfully completed multiple proofs of concept for SANTCEHTURE clients. In January, SANTECHTURE and CorroHealth jointly hosted the Arab Health reception focused on AI and Revenue Cycle Management (RCM) which is backed by leading institutional investors Gulf Capital and Shorooq Partners, has seen a phenomenal increase in demand for its advanced deep tech RCM solutions in the GGC and across regional markets, and this partnership will support yet another leap ahead in advancing innovation and value CEO Pat Leonard said, 'This is an exciting step forward for CorroHealth, as we combine our technological capabilities with a local company based in the GCC region. CorroHealth joining forces with SANTECHTURE brings the best of both worlds to provide clients in the region with unsurpassed RCM capabilities to protect hospitals' bottom lines and help to ensure their financial future.'SANTECHTURE Founder and CEO Anas Batikhi said, 'The pairing of SANTECHTURE's unique leading-edge solutions with CorroHealth's AI driven innovations in the RCM technology space is truly unrivalled. We are especially thrilled to be cementing further our working relationship with CorroHealth and leading the intelligent automation drive to support our clients and partners with their RCM digital transformation journey, delivering on cost reduction and improved revenue outcomes.'Gulf Capital Managing Director Mohammad Madani added, 'We are proud to have been early backers of SANTECHTURE and to now support this landmark partnership between SANTECHTURE's and CorroHealth. This strategic investment is a strong validation of SANTECHTURE's leadership in intelligent RCM solutions across the GCC and marks a pivotal milestone in its growth journey. We are confident this collaboration will unlock significant value for healthcare providers in the region.' Bilal Mushtaq, MD, CorroHealth's Executive Vice President of Global Growth and Strategy for GCC market expansion said 'This strategic investment and partnership marks a pivotal step forward in our growth strategy, reinforcing our commitment to innovation and delivering greater value to a new market. This is not just a collaboration but a shared vision to forge a new path towards providing excellence in revenue cycle management.' © 2000 - 2025 Al Bawaba ( Signal PressWire is the world's largest independent Middle East PR distribution service.
Al Bawaba
29-05-2025
- Al Bawaba
Navy patrol plane crashes killing 4 in South Korea
Seoul, May 29 (QNA) - A Navy patrol plane carrying four people crashed on a mountain in the southeast of South Kores on Thursday, South Korean authorities said. "A P-3 maritime patrol aircraft that took off for training from an air base in Pohang crashed at a nearby location due to unidentified reasons," the Navy said in a notice to reporters. The Navy confirmed that four people were aboard the aircraft. It has launched an investigative unit to look into further details, including casualties. Meanwhile, firefighters are continuing their efforts at the scene to control the raging fire in the area. (QNA)
